| Name | Title | Contact Details |
|---|---|---|
Devon Sharp |
Associate General Counsel | Profile |
Grant Riedesel |
Head of Legal, Corporate Development | Profile |
Tim Stow |
Global Head of Ethics and Compliance | Profile |
Sean Griffin |
Vice President of Regulatory Affairs | Profile |
Correctional Healthcare Management is a Englewood, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Tri-State Clinical Laboratory Services, LLC is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Fluresh is a premium vertically integrated medical & adult use cannabis company obsessed with quality and wellness. We believe that each individual connection between a patient and cannabis is unique, dynamic and matchless.
We offer a unique suite of solutions, with a unique perspective on clinical research development. We focus on bringing together best-in-class science, technology and service to drive superior clinical outcome results for our clients and for their patients. Increasing the Power of Clinical Research Data.
Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company`s focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV. Bionor Pharma`s most advanced product candidate is Vacc-4x, which is also the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Pharma`s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through collaboration with Celgene, is investigating Vacc-4x and the HDAC inhibitor romidepsin in the REDUC study. In May 2015, Bionor Pharma announced promising results from an interim analysis of Part B of the REDUC study. In the study, Vacc-4x and romidepsin are explored as a possible treatment regimen to reduce the persistent latent viral reservoir in HIV infected patients on anti-retroviral treatment. Results are expected in the second half of 2015. Bionor Pharma is headquartered in Oslo, Norway, with offices in Copenhagen and New York.